Sign in
CompletedPhase 2

Study of SAR447537 (INBRX-101) Compared to Plasma-derived A1PI Therapy in Adults With AATD Emphysema

Key facts

Who runs it
Sanofi
Where
Birmingham, Danbury, Denver, DuBois, Gainesville, Hannibal, Hershey, Houston, Indianapolis, Los Angeles, Maywood, Miami, Minneapolis, New York, Philadelphia, Phoenix, Portland, Sacramento, Salt Lake City, Spartanburg, and Tampa, United StatesSee the 39 sitesAlso in 8 other countries, 28 sites
Trial code
Status
Completed
Phase
Phase 2
People taking part
99 people enrolled
Started
12 Oct 2023
Ended
6 Aug 2025
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • SAR447537
  • Zemaira
Record updated
11 August 2025

Who can take part

Age
18 years to 80 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 16 criteriaShow less

Who can take part

  • Males or females 18-80 years of age, inclusive, at the time of screening
  • Diagnosis of AATD
  • Evidence of emphysema secondary to AATD
  • FEV1 of ≥ 30% and ≤ 80% predicted at screening
  • Current non-smoking status

Who cannot take part

  • Receipt of A1PI augmentation therapy within 5 weeks prior to the first dose of study drug
  • Received IV immunoglobulins, monoclonal antibodies and/or other biologic therapies within 30 days
  • On waiting list for lung or liver transplant
  • Acute respiratory tract infection or COPD exacerbation within 4 weeks prior to or during screening
  • Known or suspected allergy to components of SAR447537 (INBRX-101), A1PI or human IgG
  • Known or suspected diagnosis of type 1 diabetes or diagnosed with uncontrolled type 2 diabetes
  • Active cancers or has a history of malignancy within 5 years prior to screening
  • History of unstable cor pulmonale
  • Clinically significant congestive heart failure
  • Known selective or severe Immunoglobulin A (IgA) deficiency
  • Evidence of decompensated cirrhosis

Where in United States

Also in 8 other countries, 28 sites

  • University of Alabama at BirminghamBirmingham, United States
  • University of Alabama at Birmingham- Site Number : 105Birmingham, United States
  • Western Connecticut Medical GroupDanbury, United States
  • National Jewish Medical and Research CenterDenver, United States
  • National Jewish Medical and Research Center- Site Number : 123Denver, United States
  • Clinical Research Associates Of Central PA , LLC- Site Number : 128DuBois, United States
  • Clinical Research Associates of Central Pa, LLCDuBois, United States
  • University of FloridaGainesville, United States
  • University of Florida College of Medicine- Site Number : 101Gainesville, United States
  • Hannibal ClinicHannibal, United States
  • Hannibal Regional Healthcare System-HRMG-Hannibal- Site Number : 111Hannibal, United States
  • Penn State Health Milton S. Hershey Medical CenterHershey, United States
  • Penn State Health Milton S. Hershey Medical Center- Site Number : 122Hershey, United States
  • Houston Methodist HospitalHouston, United States
  • Houston Methodist Hospital- Site Number : 113Houston, United States
  • Indiana UniversityIndianapolis, United States
  • David Geffen School of MedicineLos Angeles, United States
  • David Geffen School of Medicine- Site Number : 124Los Angeles, United States
  • Loyola University Medical CenterMaywood, United States
  • Loyola University Medical Center- Site Number : 112Maywood, United States
  • Bruce W. Carter Miami VA Medical Center - NAVREF - PPDS- Site Number : 114Miami, United States
  • University of MiamiMiami, United States
  • M Health Fairview Clinics and Surgery Center - MinneapolisMinneapolis, United States
  • M Health Fairview Clinics and Surgery Center - Minneapolis- Site Number : 125Minneapolis, United States
  • Columbia University Irving Medical Center- Site Number : 104New York, United States
  • Temple University HospitalPhiladelphia, United States
  • Temple University Hospital- Site Number : 130Philadelphia, United States
  • St Joseph's Hospital and Medical Center- Site Number : 126Phoenix, United States
  • St. Joseph's Hospital and Medical CenterPhoenix, United States
  • Oregon Health and Science UniversityPortland, United States
  • Oregon Health and Science University- Site Number : 117Portland, United States
  • UC Davis Comprehensive Cancer Center- Site Number : 110Sacramento, United States
  • UC Davis Medical CenterSacramento, United States
  • University Of Utah HealthSalt Lake City, United States
  • University of Utah Health Care- Site Number : 106Salt Lake City, United States
  • Velocity Clinical Research - Spartanburg - PPDSSpartanburg, United States
  • Velocity Clinical Research - Spartanburg - PPDS- Site Number : 120Spartanburg, United States
  • Pulmonary and Sleep of Tampa BayTampa, United States
  • Pulmonary and Sleep of Tampa Bay- Site Number : 115Tampa, United States

About the trial

What the trial wants to find out

Phase 2 study to compare SAR447537 (INBRX-101) to plasma derived A1PI therapy in adults with AATD emphysema

The 3 groups in the trial

  • SAR447537 (INBRX-101) Q3WTreatment being tested

    IV every 3-weeks (Q3W) and placebo (normal saline)

    Treatment: SAR447537

  • SAR447537 (INBRX-101) Q4WTreatment being tested

    IV every 4-weeks (Q4W) and placebo (normal saline)

    Treatment: SAR447537

  • Zemaira (A1PI)Existing treatment, for comparison

    60 mg/kg IV once weekly (QW) and placebo (normal saline)

    Treatment: Zemaira

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
Phase 2, Double-Blind, Randomized, Active-Control, Parallel Group Study to Assess the Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Safety of SAR447537 (INBRX-101) Compared to Plasma-Derived Alpha1-Proteinase Inhibitor (A1PI) Augmentation Therapy in Adults With Alpha-1 Antitrypsin Deficiency (AATD) Emphysema
Record updated
11 August 2025